-
Abbreviations
- BMP
- bone morphogenic protein
- FABP
- fatty acid binding protein
- FAC
- ferric ammonium citrate
- FBS
- fetal bovine serum
- FDR
- false discovery rate
- FTH
- ferritin heavy chain
- HJV
- hemojuvelin
- LC-MS
- liquid chromatography–mass spectrometry
- LC-MS/MS
- tandem liquid chromatography–mass spectrometry
- MNAM
- N1-methylnicotinamide
- NAD+
- nicotinamide adenine dinucleotide
- NADH
- reduced nicotinamide adenine dinucleotide
- NADP
- nicotinamide adenine dinucleotide phosphate
- NAM
- nicotinamide
- NNMT
- nicotinamide N-methyltransferase
- PPAR
- peroxisome proliferator activated-receptor
- SAH
- S-adenosyl homocysteine
- SAM
- S-adenosyl methionine
- shRNA
- short hairpin RNA
- Smad
- mothers against decapentaplegic
- WT
- wild type
Iron is a critical element in all mammals. It is required for the transport of oxygen throughout the body, for DNA synthesis, and for respiration. Because of its ability to catalyze the production of reactive oxygen species by way of the Fenton reaction, iron excess causes tissue injury and even organ failure. As mammals have no active means of excreting iron, iron homeostasis is regulated by adjusting the amount of iron absorbed from the diet in the duodenum or released from storage in macrophages. This is accomplished by hepcidin, an iron regulatory peptide hormone that interacts with the iron exporter ferroportin (SLC40a1) to cause its internalization and degradation. The liver is the major source of hepcidin; thus, the liver plays a critical role in sensing and responding to systemic iron overload. Iron sensing in the mouse or human liver occurs through increases in bone morphogenic protein (BMP) expression and activation of mothers against decapentaplegic (Smad) signaling. The BMP coreceptor hemojuvelin (HJV) interacts with BMP receptors on the hepatocyte membrane to potentiate Smad signaling and increase transcription of hepcidin. Deficiency in hepcidin or HJV is associated with iron overload both in human patients and in mouse models.
As the prevalence of obesity is rising throughout the developed world and is associated with increased rates of diabetes, hyperlipidemia, and steatohepatitis, the interplay of energy metabolism and iron metabolism is an increasing area of interest. Obesity has been associated with iron deficiency and an impaired response to oral iron supplementation in children and adolescents. Although the mechanisms governing the effect of obesity on iron absorption are not completely understood, obesity has been associated with lower serum iron levels but higher serum levels of C-reactive protein, transferrin receptor, ferritin, hepcidin, leptin, and interleukin-6. On the other hand, increased body iron stores are associated with an increased risk of diabetes mellitus and alterations in hepatic glucose metabolism.
Niacin, also known as vitamin B3, includes nicotinic acid and nicotinamide (NAM). It is an essential vitamin that has been used for many years to reduce serum cholesterol levels. NAM is a precursor for nicotinamide adenine dinucleotide (NAD+), the cofactor for numerous enzymes involved in the oxidation of energy sources and the conversion of carbohydrates to lipids. The enzyme nicotinamide N-methyltransferase (NNMT) (Fig. A), alters NAM to N1-methylnicotinamide (MNAM) using the universal methyl donor S-adenosyl methionine (SAM). SAM is converted in the process to S-adenosyl homocysteine (SAH). Recent studies have demonstrated that NNMT deficiency in adipocytes protects against diet-induced obesity by increasing energy expenditure, while NNMT in hepatocytes regulates glucose, lipid, and cholesterol metabolism.
Mouse models reveal the interactions of iron overload and cellular metabolism. (A) The function of NNMT. NNMT catalyzes the methylation of NAM to MNAM and converts the methyl donor SAM to SAH. (B) Dietary and genetic models of iron overload. For the dietary iron-overload model, 5-week-old WT C57BL6 male mice were placed on a soy-free diet (AIN-93G) that was iron deficient (2.5 mg/kg, n = 3), iron sufficient (37.5 mg/kg, n = 3), or high iron (1,000 mg/kg, n = 3). For the genetic iron-overload model, 5-week-old mice that were either WT or HJV–/– gene mice (n = 2 per group) were maintained on the iron-deficient diet (2.5 mg/kg iron). After 50 days, the mice were killed and RNA and polar metabolites were extracted for next-generation sequencing or LC-MS/MS analysis, respectively.
In this report, we employed RNA sequencing and metabolomic approaches to identify the pathways affected by iron overload in mouse hepatocytes. We found that pathways regulating glucose and NAM metabolism were significantly altered in both a dietary model of iron overload and a genetic model, the HJV knockout mouse, and that NNMT was significantly down-regulated in both models. In a group of obese patients, we discovered that hepatic NNMT transcript levels inversely correlated with measures of body iron stores, including serum iron, serum ferritin, and serum transferrin saturation levels. Furthermore, we demonstrated that iron loading human or mouse hepatocytes in vitro suppressed NNMT expression. Adenoviral knockdown of NNMT expression in mouse hepatocytes enhanced iron-induced cytotoxicity and increased expression of genes responsive to oxidative or endoplasmic reticulum stress. Taken together, these findings indicate that hepatocyte iron overload suppresses NNMT transcript levels, which in turn exacerbates the toxic effects of iron.
Materials and Methods MOUSE STRAINS, RNA PREPARATION, AND MEASUREMENT OF NONHEME IRON LEVELSEthical approval was obtained from the institutional animal care and use committee of Beth Israel Deaconess Medical Center (Animal Welfare Assurance #A3153-01; Boston, MA) in accord with national and international guidelines. All wild-type (WT) mice were C57BL6 males (Jackson Laboratory, Bar Harbor, ME). Professor Nancy Andrews (Jackson Laboratory) provided HJV knockout (HJV−/−) mice on a C57BL6 background. For the dietary study, at 5 weeks of age, the mice were transitioned to a soy-free diet (AIN-93G; Bioserv, Flemington, NJ) containing different amounts of iron per kilogram of food: iron deficient (2.5 mg/kg, n = 3), iron sufficient (37.5 mg/kg, n = 3), or iron excess (1,000 mg/kg, n = 3). For the genetic study, 5-week-old mice that were either WT or HJV–/– (n = 2 mice per group) were maintained on the iron-deficient diet. After 50 days, the mice were killed and liver RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Hepatic nonheme iron stores were measured using the bathophenanthroline method as described.
RNA SEQUENCINGOne microgram of RNA from each sample was sequenced with a HiSeq 2000 (Illumina, Inc., San Diego, CA). Additional bioinformatics and analysis methods are provided in the
Pathway analysis was performed using DAVID Bioinformatics Resources 6.7.
METABOLOMICS SAMPLE PREPARATION AND ANALYSISWe extracted 5-10 mg mouse liver tissue in 80% high-performance liquid chromatography-grade methanol, as described, then lyophilized and resuspended the extract in 20 µL of liquid chromatography–mass spectrometry (LC-MS)-grade water. Next, 5-10 µL of each sample was autoinjected into the QTRAP 5500 tandem LC-MS (LC-MS/MS) system (AB Sciex, LLC, Framingham, MA). Multiquant 2.0 software (AB Sciex, LLC) was used to quantify chromatographic peak areas. The Linear Models for Microarray Analysis package from the Bioconductor project was used to identify differentially expressed molecules among different groups compared to controls. Technical replicates were averaged, and the biologically distinct sample groups were compared by fitting a linear model for each variable (normalized expression values) and applying empirical Bayes smoothing to identify differentially expressed molecules. For pathway analysis, the differentially expressed molecules (P ≤ 0.05 and fold change > 2) were grouped into pathways using Metaboanalyst 3.0.
QUANTITATIVE REAL-TIME REVERSE-TRANSCRIPTION POLYMERASE CHAIN REACTIONWe extracted RNA and generated complementary DNA according to the described method to measure the transcript levels of hepcidin, NNMT, and other genes by quantitative real-time reverse-transcription polymerase chain reaction using primers and probes as described (
Cryopreserved human hepatocytes (BioreclamationIVT LLC, Waterbury, NY) were plated at 2 × 105 hepatocytes per well in tissue culture-treated 24-well polystyrene plates (Eppendorf, Hauppauge, NY) coated with rat tail type I collagen (50 μg/mL) patterned into microdomains as described. The hepatocytes were cultured in Dulbecco Modified Eagle Media with high glucose, 10% fetal bovine serum (FBS), 1% insulin, transferrin, selenous acid premix (#354352; BD Biosciences, Bedford, MA), glucagon 7 ng/mL, dexamethasone 40 ng/mL, and 1% penicillin–streptomycin. Seeding of 3T3-J2 murine embryonic fibroblasts (9 × 104 cells in each well of a 24-well plate) occurred 12 hours after initial hepatocyte plating and was followed by replacement of hepatocyte culture medium and addition of ferric ammonium citrate (FAC; Sigma-Aldrich, St. Louis, MO) 24 hours after initial plating. At 24 or 48 hours after initial iron supplementation, cells were either fixed with 4% paraformaldehyde for 15 minutes or lysed for RNA extraction using the RNeasy kit (Qiagen). After washing the fixed cells with phosphate-buffered saline twice, the hepatocytes were stained with HCS Deep Red LipidTOX neutral lipid stain (Thermo Fisher, Waltham, MA), which was added to each well (1:500) for 30 minutes. The hepatocytes were then imaged using a Nikon Eclipse Ti-E microscope.
ADENOVIRAL VECTORSAdenoviral vectors containing NNMT complementary DNA or short hairpin RNA (shRNA) against NNMT were constructed previously as described and purified by two rounds of cesium chloride centrifugation. Control viruses contained either green fluorescent protein or irrelevant shRNA. The titers of the purified viruses ranged from 5 × 1010 to 20 × 1010 plaque-forming units/mL.
PRIMARY MOUSE HEPATOCYTE ISOLATION, CULTURE, AND ADENOVIRUS KNOCKDOWNPrimary mouse hepatocytes were isolated from 8-week-old C57BL6 male mice by the collagenase perfusion method. Viable hepatocytes were enriched by Percoll gradient centrifugation. The hepatocytes were seeded on collagen-coated plates at a density of 300,000/mL in Williams' E medium/5% FBS. After a 4-hour attachment period, the medium was replaced with fresh Williams' E medium/5% FBS. Primary hepatocytes were infected by overnight exposure to adenovirus in Williams' E medium at a multiplicity of infection of 3 or 10. For NNMT knockdown, the hepatocytes were cultured for 96 hours to allow for the degradation of the endogenous protein. The medium was supplemented with FAC 0-150 μM 24 hours prior to the assessment of viability or extraction of RNA. Viability was assessed using 3-(4,5-dimethylthiazol 2-yl)-2,5-diphenyltetrazolium bromide as described.
HUMAN SUBJECT RECRUITMENTThe human subject cohort comprised 53 morbidly obese subjects (9 men, 44 women) undergoing elective bariatric surgery at the Endocrinology Service of the Hospital Universitari de Girona Dr. Josep Trueta (Girona, Spain) as described. All subjects gave written informed consent as part of a research protocol validated and approved by the ethical committee of the Hospital Universitari Dr. Josep Trueta (Comitè d'Ètica d'Investigació Clínica, approval number 2009046) in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. Liver samples and sera were collected at the time of surgery. RNA was extracted, and serum iron, total iron binding capacity, and ferritin levels were determined as described in
The HJV−/− mouse exhibits marked hepcidin deficiency that causes a severe iron-overload phenotype resembling the human disease juvenile hemochromatosis. While this provides a useful animal model for iron overload, we also wanted to use a model in which hepcidin transcripts increase in response to iron overload. To achieve this, C57BL6 mice were fed diets containing 2.5, 37.5, or 1,000 mg of iron per kilogram of food to produce iron deficiency, iron sufficiency, or iron overload, respectively (Fig. B). After 50 days, the mice were sacrificed and hepatic messenger RNA was extracted for next-generation sequencing while polar hepatic metabolites were isolated for analysis by LC-MS/MS. The RNA integrity number for each sample was >6. Assessments of read duplication, base call frequency, and read quality indicated excellent quality of the data.
As expected, hepatic iron levels rose with increasing iron content in the diet (1.4-fold for iron-sufficient versus iron-deficient diet and 3.1-fold for high-iron versus iron-deficient diet, n = 3 per group; P = 0.001 for high-iron diet versus iron-deficient diet) or in the HJV−/− cohort (18.5-fold for HJV−/− versus WT, n = 2 per group; P = 0.006) (Fig. A,D). Liver hepcidin transcript levels also increased with increasing dietary iron content (Fig. B) in the WT mice (8-fold for iron-sufficient versus iron-deficient diet and a further 2.6-fold for high-iron versus iron-sufficient diet; P = 0.011 for iron-sufficient versus iron-deficient diet and P = 0.001 for iron-sufficient versus high-iron diet). As expected, hepcidin expression was significantly reduced in the HJV−/− mice (Fig. E).
Dietary and genetic models of iron overload exhibit increased hepatic iron stores and decreased NNMT expression. (A,D) Nonheme iron assays, (B,E) quantitative real-time reverse-transcription polymerase chain reaction analysis of hepcidin, and (C,F) NNMT transcript levels for the (A-C) dietary iron overload, (D-F) HJV–/– mice, and controls. Hepcidin and NNMT expression are reported as fold change over control mice with (B,C) an iron-sufficient diet (37.5 mg/kg) or (E,F) WT mice. Data shown are means +/− standard error measurements. * denotes P [less than] 0.05 and ** denotes P [less than] 0.01 by Student t test compared to the (A,B) low-iron group, (C) the iron-sufficient group, or (D-F) WT; n = 3 mice per group for (A-C) and 2 mice per group for (D-F). Abbreviations: G3PD, glyceraldehyde 3-phosphate dehydrogenase; KO, knockout.
For the dietary iron-overload study, we used self-organizing maps to identify transcripts that expressed a strong association with increasing iron dose, while for the HJV−/− mice, we used FDR <0.05 and a mean fold change >2 to identify differentially regulated transcripts. We found 128 transcripts that were differentially regulated in the dietary iron study, while 688 transcripts were differentially regulated in the genetic model of iron overload. A total of 28 genes were differentially regulated in both the dietary and genetic iron-overload models. Of these genes, expression level changed in the same direction for 13 genes and in opposite directions for 15 genes (Table ). Of the genes that were negatively regulated in both models, NNMT was the second most strongly suppressed in both the dietary and genetic iron-overload models. This effect appeared to be hepcidin independent as the dietary iron-overload model exhibits high hepcidin levels while the HJV−/− mice exhibit low hepcidin levels. We used quantitative real-time polymerase chain reaction to confirm the change in gene expression in both cohorts of mice. NNMT transcript levels decreased significantly in both the dietary and genetic models of iron overload (Fig. C,F). Using the DAVID 6.7 algorithm, we found that two pathways were significantly altered in the genetic iron-overload model, peroxisome proliferator activated-receptor (PPAR) signaling and Huntington's disease genes (Table ). The differentially regulated genes included genes involved in energy metabolism and apoptosis, including several NAM-dependent genes, e.g., malic enzyme 1 (ME1) and reduced NAD [NADH]:ubiquinone oxidoreductase core subunits (Ndufa2, Ndufa7, Ndufb7, and Ndufs7).
Transcripts Identified As Significantly Altered In Expression In Both Dietary and Nutritional Iron-Overload Experiments
| Gene | Dietary Iron Overload, SOM Vector | Genetic Iron Overload, Log2 Fold Change | Q Value | Direction |
| Bhmt | −2.06 | −1.41 | 0.0081 | S |
| Nnmt | −2 | −3.35 | 0.0022 | S |
| Tfrc | −1.99 | −2.89 | 0.0022 | S |
| Mup21 | −1.94 | −1.12 | 0.0104 | S |
| Hapln4 | −1.93 | −1.29 | 0.0469 | S |
| Serpina12 | −1.78 | −4.69 | 0.0022 | S |
| Cyp17a1 | −1.56 | −1.72 | 0.0022 | S |
| Apoa4 | −1.43 | 2.37 | 0.0022 | S |
| Robo1 | −1.33 | −2.31 | 0.0022 | S |
| Gbp6 | −0.75 | −1.55 | 0.0104 | S |
| Kbtbd11 | 1.59 | 1.9 | 0.0442 | S |
| Id3 | 1.84 | 2.08 | 0.0104 | S |
| Bmp6 | 2.05 | 2.28 | 0.0104 | S |
| Igfals | −2.19 | 1.62 | 0.0022 | O |
| Syt3 | −2.09 | 2 | 0.035 | O |
| Extl1 | −1.9 | 2.16 | 0.0022 | O |
| Zap70 | −1.8 | 1.39 | 0.0437 | O |
| Serpinb8 | −1.64 | 3.19 | 0.0022 | O |
| Slco1a4 | −1.51 | 1.25 | 0.0056 | O |
| Slc10a2 | −1.48 | 2.26 | 0.0022 | O |
| Pdzk1ip1 | 1.28 | −2.14 | 0.0337 | O |
| Krt23 | 1.38 | −2.26 | 0.0022 | O |
| Fabp5 | 1.78 | −1.86 | 0.0022 | O |
| Gpr110 | 2.01 | −1.45 | 0.0293 | O |
| Hamp2 (HJV) | 2.02 | −4.23 | 0.0022 | O |
| Vtcn1 | 2.02 | 3.55 | 0.0359 | O |
| Lpl | 2.04 | −1.04 | 0.0355 | O |
| Hamp (Hepcidin) | 2.13 | −6.41 | 0.0437 | O |
The change in transcription is expressed as an SOM vector relative to the WT animals and log2 fold change relative to the low iron diet for the dietary iron overload and the genetic iron-overload models, respectively.
5Q value is the false discovery rate for the genetic iron-overload study.
6S represents transcripts that changed in the same direction; O represents transcripts that changed in opposite directions in the two models of iron overload.
Abbreviation: SOM, self-organizing map.
ANALYSIS OF METABOLOMIC CHANGES CAUSED BY IRON OVERLOADThe levels of polar metabolites extracted from the liver were compared between the dietary and genetic models of iron overload and their respective controls to identify the metabolites with absolute fold change >2 and P values ≤0.05 (
Metabolites involved in glucose and NAM metabolism are differentially regulated in response to iron overload. (A,B) All significantly differentially regulated metabolites were grouped into pathways using Metaboanalyst 3.0 in the (A) dietary and (B) genetic iron-overload models and arranged from most significant (red) to least significant (yellow). (C) Heat map demonstrating a significant increase in NAM level in the dietary iron-overload model. Abbreviations: OBP, octulose-1,8-bisphosphate; CoA, coenzyme A.
To determine if NNMT expression is associated with iron status in humans, we evaluated NNMT and ferritin heavy chain (FTH) transcript levels in liver biopsies obtained from 53 patients undergoing elective bariatric surgery and compared them to their serum iron indices. We found that NNMT transcript levels inversely correlated with measures of body iron stores (Fig. A-D), including serum ferritin (P = 0.002), percent transferrin saturation (P = 0.02), and FTH transcript levels (P < 0.0001), while there was an inverse trend with serum iron (P = 0.06). To validate whether iron loading suppresses NNMT transcript levels in human hepatocytes, we treated primary human hepatocytes with increasing doses of FAC and found a dose-dependent decrease in NNMT expression (Fig. A). Similar to our mouse models of iron overload, we observed decreased expression of acyl-coenzyme A synthetase long-chain family members 3 and 5 (ACSL3 and ACSL5) and fatty acid binding protein 4 (FABP4), all targets of PPAR-α signaling (Fig. A). Intriguingly, iron overload also increased lipid accumulation in the hepatocytes (Fig. B).
NNMT transcript levels inversely correlate with measures of iron stores. Patients undergoing elective bariatric surgery provided liver biopsies and serum samples during their surgery to measure NNMT and FTH transcript levels and serum iron indices. Hepatic NNMT transcript levels inversely correlated with (A) serum ferritin level, (B) serum iron level, (C) hepatic FTH transcript level, (D) serum transferrin saturation; n = 53 patients.
The effect of iron loading on primary human hepatocytes. Primary human hepatocytes cultured with increasing doses of iron (FAC 0-60 μM) for (A,B) 24 hours or (B) 48 hours followed by harvesting RNA for quantitative real-time reverse-transcription polymerase chain reaction or fixation and staining for intracellular lipid accumulation with HCS Deep Red LipidTOX (Thermo Fisher). (A) Increasing doses of FAC were associated with decreased transcript levels of NNMT and PPAR-signaling targets ACSL3, ACSL5, and FABP4. * denotes P [less than] 0.05, while ** denotes P [less than] 0.01 compared to no iron control. (B) Treatment with increasing concentrations of iron was also associated with increased lipid staining in the hepatocytes on light microscopy. The scale bar denotes 100 µm.
To evaluate the effects of NNMT suppression on iron-induced toxicity, we infected primary mouse hepatocytes with an adenoviral vector encoding shRNA targeting NNMT or a nontargeting control vector and treated the cells with FAC for 24 hours. We confirmed that the adenoviral vector targeting NNMT significantly decreased NNMT expression (Fig. A) while overexpression of NNMT increased NNMT transcript levels (Fig. B). Knockdown of NNMT enhanced iron-induced toxicity, as shown by decreased viability of iron-treated hepatocytes with NNMT knockdown compared to iron-treated controls infected with a nontargeting vector (Fig. C). In contrast, overexpression of NNMT increased primary mouse hepatocyte viability, even in the presence of iron overload (Fig. D). NNMT knockdown also significantly increased the iron-induced expression of FTH and markers of oxidative stress (heme oxygenase 1 and NAD(P)H quinone dehydrogenase 1) and endoplasmic reticulum stress (activating transcription factor 4) (Fig. E). In contrast, overexpression of NNMT significantly reduced iron-induced expression of FTH and activating transcription factor 4 (Fig. F).
NNMT knockdown exacerbates iron's hepatotoxicity, while overexpression improves viability. Primary mouse hepatocytes underwent (A,C,D) adenoviral knockdown of NNMT (K) or a nontargeting knockdown (C) or (B,D,F) overexpression of NNMT (O) or overexpression of GFP (C) followed by exposure for 24 hours to (A,E) FAC 30 μM, (C) 50-150 μM, (B,D,F) 100 μM, or (A,B,E,F) water and measurement of transcript levels by quantitative real-time reverse-transcription polymerase chain reaction or (C,D) viability by the MTT assay. NNMT knockdown decreased viability in the setting of iron treatment and increased expression of iron-induced transcripts related to oxidative and endoplasmic reticulum stress, while NNMT overexpression increased viability and decreased the expression of FTH and ATF4, which is a marker of endoplasmic reticulum stress. (E,F) Data shown are mean fold change in transcript abundance of iron-treated cells relative to control cells treated with water only, indicated by the dotted line. *, **, *** denote P [less than] 0.05, P [less than] 0.01, or P [less than] 0.001 compared to controls, respectively, by Student t test; n = 3 biological replicates per group. Abbreviations: ATF4, activating transcription factor 4; GFP, green fluorescent protein; HMOX1, heme oxygenase 1; KD, knockdown; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NQO1, NAD(P)H quinone dehydrogenase 1; OE, overexpression.
Using two different models of hepatic iron overload, we identified a signature of 28 transcripts that are significantly altered in expression in the setting of iron overload. This signature includes several expected changes in the transcriptional profile, including decreased transferrin receptor and increased BMP6 and Id3 (Table ). Using the HJV−/− mice, which developed nearly 10-fold higher hepatic iron overload than the dietary model, we were able to identify two pathways that were significantly altered, Huntington's disease genes and PPAR signaling (Table ). Several genes in both pathways regulate energy metabolism and require NAM derivatives for their function. ME1, an NADP-dependent enzyme, generates NADPH for fatty acid biosynthesis and decarboxylates malate, thus connecting the glycolytic and citric acid cycles. Ndufa2, Ndufa7, Ndufb7, Ndufs7 encode subunits of NADH:ubiquinone oxidoreductase, i.e., mitochondrial complex I, which transfers electrons from NADH to the respiratory chain. Under conditions of oxidative stress, complex I dissociates from a larger mitochondrial supercomplex, which can result in increased production of reactive oxygen species by complex I.
Transcripts In The Ppar and Huntington's Disease Signaling Pathways Exhibit Lower Levels In The Livers Of HJV–/– Mice Compared To Wt Mice
| Gene | Log2 Fold Change HJV–/– vs WT | Q Value | Pathway |
| CD36 | −0.74 | 5.0 × 10−5 | PPAR |
| ACSL3 | −0.73 | 1.0 × 10−4 | PPAR |
| ACSL5 | −0.80 | 1.0 × 10−4 | PPAR |
| Cyp4a12b | −0.42 | 5.0 × 10−5 | PPAR |
| DBI | −0.79 | 3.0 × 10−4 | PPAR |
| FABP2 | −0.89 | 3.5 × 10−4 | PPAR |
| FABP4 | −0.32 | 5.0 × 10−5 | PPAR |
| FABP5 | −0.54 | 5.0 × 10−5 | PPAR |
| Lpl | −0.97 | 5.0 × 10−5 | PPAR |
| ME1 | −0.63 | 1.0 × 10−4 | PPAR |
| Atp5d | 1.83 | 4.0 × 10−4 | Huntington's |
| BBC3 | 2.76 | 7.5 × 10−4 | Huntington's |
| Bax | 1.52 | 1.3 × 10−3 | Huntington's |
| Ndufa2 | 1.33 | 1.2 × 10−3 | Huntington's |
| Ndufa7 | 1.05 | 2.4 × 10−3 | Huntington's |
| Ndufb7 | 2.25 | 5.0 × 10−5 | Huntington's |
| Ndufs7 | 2.38 | 5.0 × 10−5 | Huntington's |
| Cox7a2l, Gm6969 | 1.95 | 2.0 × 10−4 | Huntington's |
| PolR2E | 1.37 | 1.9 × 10−4 | Huntington's |
| PolR2F | 1.85 | 1.2 × 10−3 | Huntington's |
| Gm8566, SOD1 | 3.48 | 3.4 × 10−3 | Huntington's |
| Uqcr11 | 2.56 | 4.0 × 10−4 | Huntington's |
| Uqcrq | 1.97 | 7.5 × 10−4 | Huntington's |
A recent transcriptional profile of the rat pancreas in the setting of iron overload demonstrated that one of the PPAR signaling targets, Fabp2, which we identified as down-regulated in our mouse model of iron overload, was significantly down-regulated in iron-overloaded rat pancreas. FABPs are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-coenzyme A esters. Others have shown in mammalian models that iron overload leads to decreased hepatic PPAR-α expression, decreased protein levels of PPAR-α targets, and alterations in protein levels of enzymes involved in glucose metabolism and fatty acid oxidation. Intriguingly, we observed decreased expression of PPAR signaling targets and increased lipid accumulation in iron-treated human hepatocytes (Fig. A,B). Conversely, others have demonstrated that iron chelation reduces steatosis and increases PPAR-γ levels in the livers of ob/ob mice, a model of obesity and type 2 diabetes mellitus. Thus, it appears that iron overload may promote hepatic steatosis.
We found that iron overload increased expression of a variety of pro-apoptotic genes implicated in Huntington's and other neurodegenerative diseases. Among the iron overload-induced genes was Bax, a pro-apoptotic protein that is regulated by nuclear factor kappa B and p53 signaling. Bax is up-regulated in the cerebral cortex and striatum in the YAC128 mouse model of Huntington's disease. In our models, iron overload also increased expression of BCL binding component 3, a pro-apoptotic protein that is involved in neurodegeneration.
NNMT DEFICIENCY EXACERBATES THE TOXIC EFFECTS OF IRON OVERLOADGiven the finding that iron overload altered the levels of transcripts and metabolites involved in energy and NAM metabolism, we were intrigued to study NNMT further. NNMT has gained attention as a potential drug target in cancer and obesity; however, it has not been previously implicated in the pathophysiology of iron overload. We discovered that NNMT is a significantly repressed transcript in both the nutritional iron-overload model and the HJV–/– mouse. In our metabolomic analysis, dietary iron overload decreased hepatic NNMT transcript levels and increased hepatic NAM levels (Fig. C), which is consistent with decreased NNMT activity. We found that NNMT transcript levels negatively correlated with body iron stores in human patients (Fig. A-D), which indicates that this association of iron overload and NNMT suppression is likely to be conserved across species. Furthermore, we discovered that adenoviral knockdown of NNMT in mouse hepatocytes exacerbated cytotoxicity and enhanced expression of transcripts associated with oxidative damage and endoplasmic reticulum stress (Fig. C,E) while overexpression of NNMT partially reversed the toxic effects of iron overload (Fig. D,F). Because of the highly variable NNMT expression in human livers (Fig. ), we hypothesize that individuals with low NNMT expression may be predisposed to the adverse consequences of iron overload.
Whether genetic polymorphisms in NNMT increase the risk of liver and cardiovascular disease is an area of ongoing investigation. NNMT's action generates SAH, which is converted to homocysteine through SAH hydrolase. Genetic variation in the NNMT locus has been linked to hyperhomocysteinemia, a risk factor for cardiovascular disease. Over 200 single nucleotide polymorphisms have been identified, primarily in the noncoding regions of NNMT. One NNMT polymorphism in the noncoding region, rs694539, has been associated with hyperhomocysteinemia and with nonalcoholic steatohepatitis, while another polymorphism in the coding region, rs1941404, is associated with hyperlipidemia. The effect of these genetic polymorphisms on iron homeostasis has not yet been explored.
Mechanistically, NNMT regulates cellular metabolism by diverse pathways, including histone and protein methylation, and stabilization of the NAD+-dependent deacetylase sirtuin 1 through generation of MNAM, which serves as both a methyl and NAM sink. In cancer cell lines cultured in physiological levels of methionine, NNMT knockdown increases SAM to SAH ratios, which increases protein methylation, while NNMT overexpression has the opposite effect. In vivo models of NNMT deficiency have focused on the effects on glucose and lipid metabolism. Antisense knockdown of NNMT in mice that were fed a high-fat diet decreased the extent of obesity and increased methylation of histone H3 lysine 4 in white adipose tissue. Liver-specific knockdown of NNMT in mice fed a high-fat diet increased serum and liver cholesterol levels, but the addition of NNMT's product MNAM to the diet reversed these effects.
In conclusion, we describe global changes in gene expression and metabolites in genetic and nutritional iron overload and implicate NNMT for the first time in the metabolic effect of iron. In future studies, we hope to identify the mechanisms by which down-regulation of NNMT exacerbates the toxic effects of iron overload and determine whether NNMT may be a drug target for iron-overload syndromes.
AcknowledgmentWe thank Dr. Jon Asara, Mass Spectrometry Core, Beth Israel Deaconess Medical Center, for performing the metabolomic analysis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2017. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Iron overload causes the generation of reactive oxygen species that can lead to lasting damage to the liver and other organs. The goal of this study was to identify genes that modify the toxicity of iron overload. We studied the effect of iron overload on the hepatic transcriptional and metabolomic profile in mouse models using a dietary model of iron overload and a genetic model, the hemojuvelin knockout mouse. We then evaluated the correlation of nicotinamide N‐methyltransferase (NNMT) expression with body iron stores in human patients and the effect of NNMT knockdown on gene expression and viability in primary mouse hepatocytes. We found that iron overload induced significant changes in the expression of genes and metabolites involved in glucose and nicotinamide metabolism and that NNMT, an enzyme that methylates nicotinamide and regulates hepatic glucose and cholesterol metabolism, is one of the most strongly down‐regulated genes in the liver in both genetic and dietary iron overload. We found that hepatic NNMT expression is inversely correlated with serum ferritin levels and serum transferrin saturation in patients who are obese, suggesting that body iron stores regulate human liver NNMT expression. Furthermore, we demonstrated that adenoviral knockdown of NNMT in primary mouse hepatocytes exacerbates iron‐induced hepatocyte toxicity and increases expression of transcriptional markers of oxidative and endoplasmic reticulum stress, while overexpression of NNMT partially reversed these effects. Conclusion: Iron overload alters glucose and nicotinamide transcriptional and metabolic pathways in mouse hepatocytes and decreases NNMT expression, while NNMT deficiency worsens the toxic effect of iron overload. For these reasons, NNMT may be a drug target for the prevention of iron‐induced hepatotoxicity. (Hepatology Communications 2017;1:803–815)
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Division of Hematology/Oncology; Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA
2 Department of Medicine, Harvard Medical School, Boston, MA; Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Boston, MA
3 Department of Physiological Sciences, University of Florida, Gainesville, FL
4 Division of Gastroenterology and Hepatology, Weill Cornell Medical School, New York, NY
5 Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona, Hospital de Girona Dr. Josep Trueta and Universitat de Girona, Girona, Spain; CIBER Fisopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain
6 Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, MA




